The comparison of therapeutic effects of Omega-3 with Olenzapine for the management of Schizophrenia positive syndromes; a chohart study at Nishtar Medical University, Multan
DOI:
https://doi.org/10.17720/rtyb6685Keywords:
Schizophrenia, Hallucinations, Antipsychotic Medications, Olanzapine, Olanzapine Augmentation, Ω-3 Fatty Acid, PANSS, Delusions.Abstract
Schizophrenia: the complex, chronic mental health disorder characterized by hallucinations, delusions, emotional and social disconnection. Several antipsychotic medications have shown efficacy in managing symptoms but researchers continue to explore innovative approaches for treatment. The aim of study was to examine the potential advantages of combining olanzapine with Ω-3 fatty acids. In this research a randomized controlled design was used, dividing 45 individuals into three groups with schizophrenia, already stabilized on olanzapine and receiving olanzapine alone, second group received olanzapine and Ω -3 supplements combination while third group comprising 15 healthy individuals prone to stress. The outcomes were compared across these groups. This study aimed to shed light upon the potential benefits of omega-3 fatty acids as the adjunct schizophrenia treatment. For the assessment of remarkable outcomes PANSS scale was employed for 6 Months. The follow up of 4 weeks on regular basis indicated the significant outcomes upon all 3 groups of the study. The 1st Group received olanzapine only and there was no significant improvement, instead the symptoms remain stable. The 2nd Group was treated with the combination of Olanzapine + Ω -3 supplements and substantial progress was recorded in the positive as well as general physiological symptoms. The 3rd group comprises of healthy individuals prone to stress received Ω-3 fatty acids, and the response was satisfactory, indicating overall symptoms improvements. All the parameters showed significant results, as measured by the PANSS scale. The study's preliminary findings suggest that the combination of olanzapine and Ω-3 fatty acids led to greater reductions in PANSS total scores compared to olanzapine alone, indicating a potential benefit of Ω-3 fatty acids in mitigating the severity of schizophrenia symptoms. The study's results support the possibility of Ω-3 fatty acids as a supplementary treatment to enhance the effectiveness of olanzapine in managing schizophrenia
Downloads
References
Butler, E., Pillinger, T., Brown, K., Borgan, F., Bowen, A., Beck, K., & Howes, O. D. (2022).
Real-world clinical and cost-effectiveness of community clozapine initiation: mirror
cohort study. The British Journal of Psychiatry, 221(6), 740-747.
Cole D Sang, Aidan F Mullan in 2022).Update on the treatment of Parkinson’s disease
psychosis: role of pimavanserin M.D., 1143-1151. Crosstalk between Schizophrenia and
Metabolic Syndrome:The Role of Oxytocinergic Dysfunction
Dong, W., Liu, Y., Sun, J., Liu, Y., Sun, Z., & Bai, R. (2022). Temporal trends in the incidence
and disabilityadjusted life years of schizophrenia in China over 30 years. . . Frontiers in
Psychiatry, 13, 831188.,13,831188.
Altman, J., Brunner, R. L., & Bayer, S. A.(1973). The hippocampus and behavioral maturation.
Behavioralbiology, 8(5), 557-596. Arieti,S.(1955).Interpretation of schizophrenia. Author
links open overlay pane lWayneS Fenton a, Joseph Hibbeln b, Michael Knable.
Eaton,W.W.,Martins,S.S.,Nestadt,G.,Bienvenu,O.J.,Clarke,D.,&Alexandre,P..(2008).Theburden
of mental disorders. .Epidemiologic reviews, 30(1),1-14.
Filiou, M. D., Arefin, A. S., Moscato, P., & Graeber, M. B. . (2014). ‘Neuro inflammation’
differs categoricallyfrom inflammation: transcriptomes of Alzheimer's disease, Parkinson
's disease, schizophrenia andinflammatorydiseasescompared.Neurogenetics.,15.
Fonseca, L., Diniz, E., Mendonça, G., Malinowski, F., Mari, J.,&Gadelha, A.(2020).
Schizophrenia and COVID-19: risks and recommendations. Brazilian Journal of
Psychiatry, 42, 236-238. . Schizophrenia andCOVID-19:risk,42, 236-238.
Gottesman,I.I.,Shields,J.,&Hanson,D.R..(1982).Schizophrenia..Legge,S.E.,Cardno, A.G.,
Allardyce,J.,Dennison,C.,Hubbard,L.,Pardiñas,A.F.,...&Walters,J. T..(2021).Associations
between schizophrenia polygenic liability, symptom dimensions, and cognitive ability in
schizophrenia.JAMApsychiatry,78(10),1143-1151..JAMA psychiatry, 78(10), 143-115 1.
,10,
Leirer,D.J.,Iyegbe,C.O.,DiForti,M.,Patel,H.,Carra,E.,Fraietta,S.,...&Newhouse,S.J.(2019).Differe
ntialgene expression analysis in blood of first episode psychosis patients. . Differential
gene expressionanalysisin blood of firstepisodepsychosispatients.Schizophrenia research,
,88-97.
Achinewhu, S.C., Ogbonna, C.C. and Hart, A.D. (1995) Chemical Composition of Indigenous
Wild Herbs, Spices, Nuts and Leafy Vegetables Used as Food. Plant Foods for Human
Nutrition, 48, 341-348.
Michaela,P.,Mária,K.,Silvia,H.,&Ľubica,L..BisphenolAdifferentlyinhibitsCaV3.1,CaV3.2andCa
V3.3calcium channels. Naunyn-Schmiedeberg's archives of pharmacology, 387, 153-163.
Naunyn-Schmiedeberg'sarchives of pharmacology,387,153=163.
Regier, D. A. (2022). Developmental History of Mood Disorder Classification. The American
Psychiatric Association Publishing Text book of Mood Disorders, 15.
Sommer, I. E., Tiihonen, J., van Mourik, A., Tanskanen, A., & Taipale, H. . (2020). The clinical
course ofschizophrenia in women and men—a nation-wide cohort study. NPJ
schizophrenia, 6(1), 12. NPJschizophrenia,, 6(12).
Wayne S. Fenton(2019) Weight Gain and New Onset Diabetes Associated with Olanzapine and
Risperidone Weinberger,D.R.,&Harrison,P.(Eds.)..(2011).Schizophrenia.
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
